Scientists have made a significant advance toward understanding the regulation of blood stem cells and the complex, lifelong process of blood cell formation. A research study published in the February issue of Developmental Cell expands on previous studies by using adult animals to examine the role of a key gene known to be required for blood cell formation. Information gained from this research will be useful for future studies aimed at directing stem cell differentiation in a variety of potential therapeutic contexts.
Blood cell formation, known as hematopoiesis, begins with a hematopoietic stem cell (HSC), which can either "self-renew" and make more copies of itself or differentiate into either red blood cells, various types of white blood cells, or platelets. The genes that control proliferation and differentiation have been difficult to study using traditional gene disruption methods because loss of genes thought to be critical for this process often results in embryonic death, making it impossible to study the role of the gene of interest in mature animals.
Dr. Michael P. Cooke and colleagues from the Genomics Institute of the Novartis Research Foundation in San Diego found a way around this problem. The researchers used random mutagenesis and screening to find animals with hematopoiesis defects, and they used genetics to identify the causative gene. One line mapped to a mutation in the gene c-Myb, which has a known role in regulation of blood formation.
Interestingly, they found that c-Myb is not required for every step of hematopoiesis or for every type of blood cell. Instead, c-Myb is critical for very distinct steps in the formation of specific types of blood cells. Most surprisingly, the c-Myb mutants also had a dramatic increase in the total number of HSCs, suggesting that part of the normal function of c-Myb is to hold HSC multiplication in check.
These data suggest that c-Myb is a key regulator of hematopoiesis and acts at many distinct points to control HSCs. "It is remarkable that a single transcription factor controls the diverse processes of self-renewal, proliferation, and differentiation" says Dr. Cooke. "The next challenge is to understand how c-Myb controls HSC numbers and use this information to develop compounds that can regulate stem cell proliferation and differentiation. The ability to influence stem cell fate decisions would be expected to have a major impact on the field of stem cell therapy and to provide important in vitro model systems for the identification of genes and compounds that can be used to regulate the process of stem cell differentiation."
Mark L. Sandberg, Susan E. Sutton, Mathew T. Pletcher, Tim Wiltshire, Lisa M. Tarantino, John B. Hogenesch, and Michael P. Cooke: "c-Myb and p300 Regulate Hematopoietic Stem Cell Proliferation and Differentiation"
The other members of the research team include Mark L. Sandberg, Susan E. Sutton, Mathew T. Pletcher, Tim Wiltshire, Lisa M. Tarantino, John B. Hogenesch, and Michael P. Cooke of the Genomics Institute of the Novartis Research Foundation.
Publishing in Developmental Cell, Volume 8, Number 2, February 2005, pages 153–166. http://www.developmentalcell.com/
Materials provided by Cell Press. Note: Content may be edited for style and length.
Cite This Page: